Generic Fenoglide for High Cholesterol Launched by Mylan
Mylan is releasing a generic version of Santarus' fenofibrate (Fenoglide) tablets.
Mylan is releasing a generic version of Santarus’ fenofibrate (Fenoglide) tablets.
The FDA approved the manufacturer’s abbreviated new drug application for the 40-mg and 120-mg tablets on July 6, 2016.
The product may be used as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, and apolipoprotein B and to increase high-density lipoprotein in adult patients with primary hypercholesterolemia or mixed dyslipidemia.
In the year ending April 30, 2016, fenofibrate tablets had US sales of around $28.6 million, IMS Health reported.
Mylan hopes to receive FDA approval for nearly 250 additional abbreviated new drug applications still pending.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025
- Advise Patients About Self-Care Measures to Treat Mild to Moderate GI Issues
September 18th 2025